3TKH
Crystal structure of Chk1 in complex with inhibitor S01
Summary for 3TKH
Entry DOI | 10.2210/pdb3tkh/pdb |
Descriptor | Serine/threonine-protein kinase Chk1, SULFATE ION, 1-(morpholin-4-yl)-2-[4-(2-{[5-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}pyridin-4-yl)piperazin-1-yl]ethanone, ... (4 entities in total) |
Functional Keywords | chk1, kinase, cell checkpoint, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Cellular location | Nucleus: O14757 |
Total number of polymer chains | 1 |
Total formula weight | 37483.79 |
Authors | |
Primary citation | Dudkin, V.Y.,Rickert, K.,Kreatsoulas, C.,Wang, C.,Arrington, K.L.,Fraley, M.E.,Hartman, G.D.,Yan, Y.,Ikuta, M.,Stirdivant, S.M.,Drakas, R.A.,Walsh, E.S.,Hamilton, K.,Buser, C.A.,Lobell, R.B.,Sepp-Lorenzino, L. Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates. Bioorg.Med.Chem.Lett., 22:2609-2612, 2012 Cited by PubMed Abstract: Pyridyl aminothiazoles comprise a novel class of ATP-competitive Chk1 inhibitors with excellent inhibitory potential. Modification of the core with ethylenediamine amides provides compounds with low picomolar potency and very high residence times. Investigation of binding parameters of such compounds using X-ray crystallography and molecular dynamics simulations revealed multiple hydrogen bonds to the enzyme backbone as well as stabilization of the conserved water molecules network in the hydrophobic binding region. PubMed: 22374217DOI: 10.1016/j.bmcl.2012.01.110 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.79 Å) |
Structure validation
Download full validation report